Hagedorn Research


Our Vision

The Novo Nordisk Haemophilia Foundation (NNHF) was set up in 2005 with the vision that all people with haemophilia or allied bleeding disorders receive care and treatment wherever they live.


One planet, different worlds

With proper diagnosis and care haemophilia and allied bleeding disorders are treatable. People can lead normal lives and have a near-normal life expectancy. This is not the situation everywhere. Particularly in the developing countries, where 75% of the global patient population lives, still many patients go undiagnosed or are inadequately treated.


Committed to bridging the gap

Realising this situation and aiming to further bridging the existing gap, Novo Nordisk, a global Danish pharmaceutical company, established the NNHF. Its formation as a grant-making non-profit organisation expresses Novo Nordisk’s commitment to corporate social responsibility. Improving access to care on a global level is a key element of this approach to impacting change.
 

A vision coming to life

We firmly believe that our vision can only be achieved through a partnership approach, which is twinned with focused on the ground activities.


Related content

Find out more about haemophilia and allied bleeding disorders
Read more

Read about all our programmes in our latest NNHF Activity Report
Read more

Find out which countries we operate in
Read more

Find out more about NNHF's identity
Read more

Our code of conduct
Read more

See all NNHF documents